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A B S T R A C T
Amyotrophic lateral sclerosis (ALS) is a disease with highly heterogenous causes, most of which remain un-
known, a multitude of possible disease mechanisms, and no therapy currently available that can halt disease
progression. However, recent advances in antisense oligonucleotides have made them a viable option for tar-
geted therapeutics for patients. These molecules offer a method of targeting RNA that is highly specific, adap-
table, and does not require viral delivery. Antisense oligonucleotides are therefore being developed for several
genetic causes of ALS. Furthermore, biological pathways involved in the pathogenesis of disease also offer
tantalizing targets for intervention using antisense oligonucleotides. Here we detail existing and potential targets
for antisense oligonucleotides in ALS and briefly examine the requirements for these drugs to reach and be
effective in clinic.
1. Introduction
Amyotrophic Lateral Sclerosis (ALS) has seemed until recently to be
refractory to therapeutic intervention. However the advent of novel
molecular medicines, in particular antisense oligonucleotides (ASOs),
has brought with it the potential for treatment. There are currently
around 35 genes linked to increased risk of ALS, accounting for ap-
proximately 15% of sporadic and 70% of familial cases (Renton et al.,
2014). They collectively implicate diverse processes in ALS pathogen-
esis; RNA processing, protein quality control, and organelle and vesicle
trafficking. Mechanistically, mutations in these genes act through gain-
of-function, loss-of-function or both. Many of these genes also modify
the behaviour or function of the RNA-binding protein TAR DNA binding
protein 43 (TDP-43), making TDP-43 and its substrates therapeutically
relevant targets.
Wildtype TDP-43 is deposited in protein aggregates in neurons and
glia in ˜96% of ALS cases, with aggregates in the remaining cases being
composed of mutant TDP-43, mutant SOD1 or mutant FUS, decorated
with degradation adaptor proteins including ubiquitin (Neumann et al.,
2006; Vance et al., 2009). Macroaggregates of TDP-43 and other pro-
teins are likely to be protective, but they signal the presence of pre-
aggregates and oligomers which are increasingly predicted to be the
toxic species (Scotter et al., 2014). Because oligomer formation is
concentration-dependent, reducing protein concentration using
targeted reduction therapies has the potential to prevent toxicity. Al-
though the autosomal dominant inheritance patterns for the vast ma-
jority of ALS genes implicate gain-of-toxic-function mechanisms, loss of
wildtype function is increasingly being reported. Respecting this bal-
ance is a major consideration for ASOs which target ALS-linked genes,
and in this review we present the case that regulators of ALS genes or
their downstream pathways may represent safer targets. In this review,
we explore available and potential ASO therapies for this complex
disease, examining the most promising targets, mechanisms of action,
and modes of delivery to patients.
2. Biology and chemistry of antisense oligonucleotides
Distinct classes of therapeutic oligonucleotides exist; siRNAs, which
engage with the RNA-induced silencing complex, and antisense oligo-
nucleotides (ASOs), which do not. Both control gene expression post-
transcriptionally through Watson-Crick base pairing, but they differ in
their chemical composition, mechanisms of action, and site of pre-
dominant subcellular activity (cytoplasm for RNA interference and
nucleus for ASOs) (Deleavey and Damha, 2012).
ASOs are short, synthetic, single-stranded molecules designed to
complement a target RNA and either modify gene expression through
enzymatic cleavage of the transcript, or sterically block the binding of
proteins involved in RNA maturation or translation (Fig. 1). The oligo-
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RNA duplexes formed can become substrates for the endonuclease
RNase H, which results in cleavage of the target mRNA and potent si-
lencing of the gene product (Lima et al., 2007). This approach, there-
fore, is ideal for forms of ALS caused by toxic gains-of-function of either
the protein or RNA. Alternatively, chemical modifications to the ASO
backbone can prevent RNase H recruitment, such that they instead
modulate gene expression through steric blockade (Deleavey and
Damha, 2012). Depending on the RNA target region, ASOs can prevent
ribosome assembly and translation, displace translation inhibitory ele-
ments, alter binding of RNA stability modulators, or alter splicing and
thus isoform expression. The splice-switching ASO SPINRAZA for spinal
muscular atrophy displaces splicing factors to convert SMN2mRNA into
SMN1-like mRNA, thus increasing protein expression of SMN1 (Finkel
et al., 2017). Therefore, ASOs can either increase or decrease protein
expression through distinct mechanisms making them a highly versatile
therapeutic.
Until recently, the poor stability, low transfection efficiency, off-
target gene silencing, and immunostimulation of ASOs hampered their
clinical implementation. Chemical improvements to ASOs, including
alternative phosphate linkages, backbone sugars, and nucleobases
(Deleavey and Damha, 2012) (Fig. 1) have yielded modified oligonu-
cleotides with increased binding affinity, nuclease resistance, cellular
uptake and endosomal release, and reduced immune activation. Cur-
rently popular are ‘gapmers’ which use modified nucleotides flanking a
central ‘gap’ of unmodified nucleotides capable of stimulating RNase H,
including Ionis’ first-in-human ALS therapy for SOD1 (Miller et al.,
2013). ‘Stereopure’ ASOs, such as Wave Life Sciences’ WVE-3972-01
against expanded C9ORF72 repeats, are individual ASOs with con-
trolled chirality at each phosphorothioate linkage, selected from the
racemic mixture of hundreds of thousands of isomers for their superior
uptake and potency (Brown, 2017). Some ASO chemistries may be
vulnerable to sequestration into stress granules by mutant RNA-binding
proteins (Bailey et al., 2017), which are frequently found in ALS, and
ASO-protein interactions can sometimes alter the potency of an ASO
(Liang et al., 2015). Nevertheless, as human therapeutics for ALS, ASOs
have many advantages over other nucleotide therapeutics including
superior bioavailability, broad CNS distribution (with intrathecal in-
jection), better cellular uptake and safety profile (Geary et al., 2015).
3. ASO targets in ALS
3.1. Direct targeting of mutant genes: allele-specific versus non-specific ASO
targeting
For ALS cases where a genetic mutation is the clear cause, allele-
specific ASO targeting is an attractive strategy because it offers the
selective removal of the mutant but not the wildtype gene product. For
TDP-43 and FUS there is clear evidence that the wildtype protein is
Fig. 1. Selected antisense oligonucleotide chemical modifications.
(a) The natural RNA/DNA structures are often modified at the internucleotide linkages (teal) and the sugar rings (orange) to improve nuclease resistance, increase
target binding affinity, and enhance pharmacokinetics while reducing toxicity. (b) Modifications to the phosphodiester backbone can be employed to improve
cellular uptake, make ASOs nuclease-resistant, and tune their ability to trigger RNase H cleavage. Gapmers contain a combination of chemical modifications. (c)
Ribose is commonly modified at the 2’ position to enhance target binding affinity, increase stability, and reduce immunostimulatory properties.
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essential for function; TDP-43 or FUS knockout from mouse embryos is
lethal, and partial knockdown postnatally causes a progressive ALS-like
disease (Iguchi et al., 2013; Hicks et al., 2000). Although C9ORF72 gene
knockout does not cause a motor phenotype in rodents, it is required for
immune function therefore reduced expression of the wildtype gene
could be detrimental (Sudria-Lopez et al., 2016). Even for SOD1, whose
function may be dispensible for development (Reaume et al., 1996),
chronic depletion in adulthood can induce motor neuron dysfunction
(Fischer et al., 2011).
An allele-specific ASO for C9ORF72, Biogen’s BIIB078, complements
the expanded repeat to selectively target mutant transcripts for de-
gradation, and is now in phase I trials (Fig. 2). Targeting upstream of
the C9ORF72 expanded repeat in animal models also selectively reduces
repeat-containing transcripts, while ASOs targeted downstream reduce
all isoforms (Lagier-Tourenne et al., 2013; Donnelly et al., 2013). An
RNase-resistant ASO (full 2-O-methoxyethyl-modified) against the ex-
panded repeat blocks RNA-binding protein recruitment to foci, which
has been proposed as a pathomechanism (Donnelly et al., 2013). Be-
cause ASOs tend to target nuclear transcripts, the relative contribution
to pathogenesis of RNA foci (nuclear) and dipeptide repeat-encoding
transcripts (cytoplasmic) may determine whether C9ORF72-linked ALS
can be treated by ASO therapy. In mutant TARDBP cases, allele-specific
targeting may be possible, given that an allele-specific siRNA afforded
near complete silencing of TDP-43M337V expression in cell lines without
affecting the wildtype protein (Nishimura et al., 2014). There are of
course some foreseeable limitations to the use of allele-specific ASOs in
ALS; i) even mutant-specific knockdown could risk loss-of-function ef-
fects (particularly for males with ALS caused by X-linked UBQLN2
mutations), and ii) the need to develop and trial specific ASOs for in-
dividual mutations. We predict that ‘personalised’ mutation-specific
ASOs will be among the next wave of therapies, but their feasibility will
be dependent upon improved patient access to genotyping, a rapid
development pipeline, and most importantly an expedited pathway to
clinical approval. Alternatively, non-allele-specific ASOs may
circumvent such issues.
A non-allele-targeting ASO for SOD1 (ISIS333611) was the first ASO
to be trialled in humans, reaching 21 patients with 15 different SOD1
genotypes (Miller et al., 2013). A non-targeting ASO has also been
developed for FUS, binding the intron 6/exon 7 junction to repress exon
7 inclusion and induce mRNA decay (Zhou et al., 2013) (Fig. 2). Al-
though the debate is ongoing, the findings in the SOD1 human trial of
only partial SOD1 knockdown in the CNS, and the absence of peripheral
SOD1 knockdown or loss-of-function toxicity, suggest that allele-spe-
cific SOD1 ASOs to avoid loss-of-function toxicity are not yet an urgent
need. Instead, the current challenge for ALS therapy researchers is to
improve target knockdown in the broader patient base, using non-al-
lele-specific ASOs.
3.2. Upstream: regulators of RNA-binding proteins as ASO targets
Given the risk of modifying certain ALS-causing genes directly, and
the fact that the majority of ALS cases are sporadic, an emerging
strategy is to use ASOs to target ALS-associated gene modifiers or pa-
thogenic pathways. Pathological misfolding, mislocalisation or post-
translational modification of wildtype TDP43 are features in almost all
cases of ALS (Neumann et al., 2006), and these features are regulated
by both the stress granule response and protein degradation pathways.
Remarkable life extensions have been observed in neurodegenerative
rodent models after reducing levels of the stress granule proteins
ATXN2 (Fig. 2) and TIA1 (Apicco et al., 2018; Becker et al., 2017). The
stress granule protein HNRNPA2/B1 is another intriguing potential
target for knockdown; its mutation causes ALS but largely through gain-
of-function mechanisms and it colocalizes to stress granules with TDP-
43 (Martinez et al., 2016). Similarly, knockdown of endogenous in-
hibitors of protein degradation pathways (Lee et al., 2010) may a
tractable strategy by which ASOs could accelerate the degradation of
ALS-linked proteins. These being fundamental cellular processes, ex-
tensive preclinical testing of such ASOs will be necessary to rule out
Fig. 2. Selected antisense oligonucleotide therapies in trial or development for ALS.
Three ASO-based therapies for ALS are currently in clinical trials with several more in development. SOD1 ISIS333611, SOD1 BIIB067, C9ORF72 BIIB078, C9ORF72
WVE-3972-01, and the ATXN2 ASO are phosphorothioate (PS)- or mixed PS/phosphodiester-backbone gapmers with 2’-O-methoxyethyl-modified ribonucleotides
flanking a central unmodified ribonucleotide stretch. For C9ORF72 WVE-3972-01, the chirality of each phosphorothioate linkage is controlled. All five stimulate
RNase H cleavage, of either the mutant transcript alone or of both wildtype and mutant transcripts, to mitigate gain-of-toxic-function; SOD1 or C9ORF72 dipeptide
repeat (DPR) polymers, C9ORF72 RNA foci formation, or aberrant recruitment of TDP-43 to stress granules by ATXN2. The FUS splice-switching ASO has a PS-linked
backbone with 2’-O-methyl-modified ribonucleotides, which targets the intron 6/ exon 7 junction to sterically block binding of auto-regulatory FUS protein and
induce exon 7 skipping. The resulting frameshift produces a premature stop codon in exon 8, inducing nonsense-mediated decay of FUS transcript and decreased FUS
protein.
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toxicity. However, given that ASO-mediated reduction of ATXN2 was
safe and effective in mice, ASOs that modify TDP-43 through the stress
granule response or other upstream targets offer the tantalising promise
of a generic therapy for almost all cases of ALS.
3.3. Downstream: RNA-binding protein-regulated transcripts as ASO targets
Splicing aberrations are a major defect downstream of RNA-binding
protein dysfunction (Colombrita et al., 2015; Humphrey et al., 2017).
Both TDP-43 and FUS regulate many transcripts in a cell type-specific
and species-specific manner, however several credible ALS-relevant
targets have emerged including POLDIP3, AGRN, ELAVL3, and MAPT.
Two recent studies identified a splicing defect in STMN2, a regulator of
microtubule dynamics, motor neuron outgrowth, and regeneration that
corresponded with downregulation of STMN2 in human post mortem
ALS tissue and which was downstream of TDP-43 dysfunction (Klim
et al., 2019). Given the success of the splice-switching ASO SPINRAZA
for spinal muscular atrophy (Finkel et al., 2017), a similar approach
might be employed for misspliced targets of TDP-43 or FUS that con-
tribute to neurodegeneration. Targets downstream of RNA-binding
protein dysfunction might also include microRNAs. Human motor
neurons expressing mutant FUS had decreased levels of the neuropro-
tective miR-375 (De Santis et al., 2017). Thus, methods to either acti-
vate or inhibit microRNAs downstream of ALS genes might also be
considered.
4. Delivery of ASOs
The mode of ASO delivery to ALS patients is crucial. It is currently
necessary to deliver ASOs via spinal (intrathecal) injection, in order
that they by-pass the blood-brain barrier (BBB). While intrathecal ad-
ministration minimises peripheral off-target effects, lumbar injections
can be challenging, or cause adverse events including pain and head-
ache (Miller et al., 2013). The risk of these events increases with regular
injections, as is required for the spinal muscular atrophy ASO SPINR-
AZA which patients receive every 4 months (Finkel et al., 2017).
Two strategies could mitigate the requirement for repeated or in-
trathecal injection; extending ASO half-life and improving their per-
meability across the BBB, respectively, although achieving both may
prove challenging. Phosphorothioate ASOs already benefit from low-
affinity plasma protein binding that reduces their renal clearance, but
their circulation lifetimes might be further extended by conjugation to
lipid- or polymer-based ‘nanocarriers’ (Geary et al., 2015). However,
many nanocarriers developed to date exhibit cytotoxicity, and are likely
to further impede BBB transit (Juliano, 2016). ASO transport across the
BBB may be best achieved by molecular-scale conjugation to substrates
of endothelial uptake processes; ASOs coupled to anti-transferrin re-
ceptor antibody or to short positively-charged cell-penetrating peptides
are transcytosed across endothelia via receptor-dependent or in-
dependent endocytosis (Juliano, 2016). Once they reach the CNS, cell
type-specific targeting of ASOs may not be necessary given the likely
role for non-neuronal cells in ALS pathogenesis (Neumann et al., 2006).
Another consideration for ASO delivery is duration, particularly
with respect to the treatment of gene carriers in the presymptomatic
phase. The risks to humans of prolonged ASO treatment will be difficult
to examine preclinically, but once presymptomatic treatment is
achievable, ASOs may bring us closer to disease prevention at least in
familial cases.
5. Discussion
ASOs are inexpensive to manufacture and offer specific targeting of
transcripts containing genetic lesions as well as upstream pathogenic
events. Genes mutated in ALS with toxic gain-of-function mechanisms
are clear targets for direct interference by antisense oligonucleotide
therapies. However, a key question underpinning selective ASO
therapies is whether the potential target causes toxicity through gain-
or loss-of-function, or both. Ideally, an ASO should modify the levels or
splicing of only mutant-bearing transcripts. However, sequence-specific
differences in ASO safety profiles will need to be well understood before
personalised ASOs become a clinical reality. Even then, considering that
mutant alleles probably retain some wildtype function in addition to
toxic gain-of-function, complete reduction of mutant-bearing tran-
scripts may not be without consequence.
Furthermore, the majority of ALS cases are sporadic in nature with
no ‘mutant’ target identified. Thus, an alternative route to employing
oligonucleotide-based therapies will be to modulate pathways im-
plicated in ALS disease pathogenesis, including protein homeostasis and
stress granule assembly. These pathways are common not only to the
vast majority of ALS but also to other neurodegenerative diseases, of-
fering further economy of scale of synthesis, and power to measure
efficacy. Sub-therapeutic targeting of several pathways could be an-
other powerful way to mitigate the risks of long-term suppression of a
single gene. Similarly, combining ASOs with currently available drugs
or small-molecule TDP-43 modulators currently under investigation
may allow for safer long-term therapy.
A number of challenges remain before the potential of ASO thera-
pies for ALS can be realised. There is a clear trade-off between bringing
ASO therapies to market quickly and delaying their availability in order
to identify the most efficacious ASO design and chemistry. The use of
preclinical model systems that accurately model disease should aid in
screening for such ASOs and this might be iterative, whereby ASOs
which have been tested in humans could become tools to identify
preclinical models with the highest predictive value. The best ASOs are
unlikely to afford disease reversal in humans, which would require
regeneration of motor neurons. However, advancements in genetic di-
agnostics alongside the rapid development of ASO chemistries and
targeting strategies mean that ASOs will be a key technology for halting
ALS progression, which would represent a major advancement for this
devastating disease.
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